Several overseas research institutes have conducted “replication studies” using N-NOSE, the world’s first biological screening technology, focusing on the reproducibility of our method. The research confirmed that the technology is reproducible as a method of identifying cancer with great accuracy, and results have been published in academic journals.
We as HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative: Takaaki Hirotsu (Hereinafter referred to as “HIROTSU”) are pleas . . .
2024.04.01On March 18, 2024, an reveiw articles on cancer screening by a third-party research team (Romania) was published in "Cancers", an oncology journ . . .
2024.03.29HIROTSU Bioscience Inc. (Head Office: Chiyoda-ku, Tokyo, Representative: Takaaki Hirotsu, hereinafter referred to as “HIROTSU) has verified the . . .
2024.02.29